SCHEMBL12376490

SCHEMBL12376490

CC(C)c1ccc2c(c1)CC(O)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 3/20 0.42
DRD2 P14416 7/20 0.41
DRD3 P35462 7/20 0.41
DRD4 P21917 4/20 0.41
RXRA P19793 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
LMNA P02545 3/20 0.40
CYP3A4 P08684 3/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
CYP2D6 P10635 2/20 0.40
HTR1A P08908 1/20 0.40
ADRB2 P07550 1/20 0.40
CASP1 P29466 1/20 0.40
TSHR P16473 2/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12376492 0.93 CYP1A2 (0.46) KARS1DRD2DRD3RXRACCNE1
SCHEMBL24648949 0.85 CHRNB2 (0.41) KARS1RXRACCNE1CDK2RXRB
SCHEMBL20889842 0.80 DRD2 (0.62) DRD2DRD3DRD4LMNAMEN1
SCHEMBL10560019 0.79 CYP3A4 (0.39) KARS1DRD2DRD3DRD4RXRA
SCHEMBL15087102 0.78 PTGS2 (0.44) KMT2ATSHRCYP1A2CYP11B1CYP11B2
SCHEMBL20890076 0.77 DRD2 (0.43) KARS1DRD2DRD3DRD4RXRA
SCHEMBL10130323 0.77 DRD2 (0.45) DRD2DRD3DRD4LMNACYP3A4
SCHEMBL20883968 0.76 GRIN2B (0.43) KARS1LMNACYP3A4MEN1KMT2A
SCHEMBL20883884 0.74 MTNR1A (0.64) KARS1RXRACCNE1CDK2RXRB
SCHEMBL20889840 0.74 KARS1 (0.43) KARS1RXRACCNE1CDK2RXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10807994-B2 Heterocyclic compounds and uses thereof NUVATION BIO INC. (US) 2020-10-20 US disclosed
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-04-11 US disclosed
US-20190106436-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-04-11 US disclosed
US-8436016-B2 Fused heterocyclic M1 receptor positive allosteric modulators Merck, Sharp & Dohme, Corp. 2013-05-07 US disclosed
US-20110201607-A1 FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck, Sharp & Dohme, Corp. 2011-08-18 US disclosed
EP-1891004-B1 PENTAFLUOROSULPHANYL-SUBSTITUTED COMPOUND AND ITS USE FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106436-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF WEE1, WEE2, NME1 KARS1 1725/4885DRD2 4370/4885DRD3 4178/4885
US-20110201607-A1 FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, OPRL1, OPRM1 KARS1 4467/4885DRD2 322/4885DRD3 478/4885
US-10807994-B2 Heterocyclic compounds and uses thereof WEE1, WEE2, CCNE1 KARS1 1301/4885DRD2 4697/4885DRD3 4560/4885
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF WEE1, WEE2, NME1 KARS1 1725/4885DRD2 4370/4885DRD3 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.